Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates positive sentiment with strong product development and strategic plans, including new product launches like Mobi Tubeless and Sigi. Despite some uncertainties in pricing and detailed guidance, the company demonstrates a clear path to growth with international expansion, pharmacy channel leverage, and type 2 diabetes initiatives. The anticipated gross margin improvements and focus on double-digit growth further support a positive outlook. While management avoided some specifics, the overall tone and strategic direction suggest a likely stock price increase in the near term.
Key Financial Performance
Revenue $249 million, record third quarter sales, driven by ASP increases on both pumps and supplies in the U.S. as well as favorable foreign currency dynamics.
Gross Margin 54%, increased approximately 3 percentage points year-over-year and 2 percentage points compared to Q2, reflecting meaningful benefit from higher ASPs, channel benefit, and scaling reductions in Mobi costs.
U.S. Sales $176 million, marking the highest third quarter to-date and second highest quarter ever, primarily driven by pricing benefits from both DME and pharmacy channels.
International Sales $74 million, record third quarter, primarily increased year-over-year due to favorable movements in foreign currency exchange rates.
Pump Shipments (U.S.) Over 20,000, slightly down from Q2 due to the pharmacy stocking benefit recognized in Q2.
Pump Shipments (International) Just over 9,000, with true market demand showing double-digit year-over-year growth in end-user pump placements.
Operating Expenses Increased 4% year-over-year, primarily attributed to SG&A investments, including U.S. sales force expansion and costs to support direct operations in Europe.
Adjusted EBITDA Returned to positive, supported by top-line growth and cost optimization efforts.
Free Cash Flow Returned to positive, ending the quarter with $319 million in total cash and investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Mobi Control app for Android: Awaiting FDA clearance to expand the worldwide addressable market.
t:slim X2 with Abbott's FreeStyle Libre 3 Plus integration: Fully available in the U.S., with positive user feedback and plans for global rollout.
Source Cloud Infrastructure: Supports Mobi expansion outside the U.S. and enables mobile applications for t:slim X2 in multiple countries.
Control-IQ+ for Type 2 diabetes: Expanded from pilot to full promotion, doubling the addressable market in the U.S.
Mobi Tubeless: Transforms Mobi into an extended wear patch pump, with a 2026 commercial launch planned.
Sigi Patch Pump: Refined design combining Mobi and Sigi platforms for a next-gen Mobi product.
Direct operations in Europe: Launching in the U.K., Switzerland, and Austria in early 2026, with plans to expand to other countries later.
Pharmacy benefit coverage: Increased to over 40% of U.S. lives for Tandem Mobi, with early uptake showing affordability and convenience.
Commercial operations modernization: Redefined processes, deployed new technology platforms, and restructured the organization to improve efficiencies.
Pharmacy channel expansion: Started selling t:slim supplies through the pharmacy benefit, improving affordability and convenience.
Organizational restructuring: Completed restructuring to enhance efficiency, with expected financial benefits in upcoming quarters.
Multichannel reimbursement strategy: Advancing pharmacy access to make AID technology more affordable and accessible.
Fully closed-loop technology: Progressing development with a goal to start a pivotal study next year.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: Awaiting FDA clearance for Mobi Control app for Android, which limits market expansion until approval is granted.
International Expansion: Transitioning to direct operations in Europe involves risks such as execution challenges, potential disruptions, and inventory buybacks from distributors.
Supply Chain and Manufacturing: Scaling up manufacturing for Mobi Tubeless and other products could face delays or inefficiencies, impacting timelines and costs.
Market Penetration: The Type 2 diabetes market is underpenetrated and requires significant development efforts, which may take time to yield results.
Pricing and Reimbursement: Dependence on pharmacy benefit expansion and pricing improvements introduces risks if adoption or coverage does not meet expectations.
Economic and Currency Risks: International sales are influenced by foreign currency exchange rates, which could negatively impact revenue.
Operational Restructuring: Recent organizational restructuring may face challenges in achieving intended efficiency gains and cost savings.
Product Development: Delays in product launches, such as Mobi Tubeless and Sigi Patch Pump, could impact competitive positioning and revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: 2025 worldwide sales are expected to reach $1 billion, with $700 million from the U.S. and $300 million internationally. U.S. sales growth is driven by new product introductions and increased pharmacy access, while international sales growth is expected despite $10 million in headwinds from distributor inventory adjustments.
Margin Projections: Gross margin for 2025 is expected to be in the range of 53% to 54%, with Q4 anticipated to achieve a record gross margin in the mid- to high 50s. For 2026, gross margin is targeted to reach at least 60% by Q4.
Capital Expenditures and Operational Changes: The company is scaling operations for larger volumes, implementing leaner operations, greater automation, and new processes. Direct operations in Europe are expected to scale in 2026, with ASPs anticipated to be at least 30% higher in direct markets compared to distributor pricing.
Product Launches and Market Trends: The Mobi Tubeless patch pump is expected to launch in 2026, featuring extended wear technology. The Sigi Patch Pump is being refined and will be marketed as the next-generation Mobi. A pivotal study for a fully closed-loop algorithm is planned for next year. The company is also expanding its Type 2 diabetes commercial efforts, doubling the addressable market in the U.S.
Business Segment Performance: Renewals in the U.S. are expected to remain strong, with more than 70% of U.S. sales generated by recurring revenue streams. Internationally, direct market sales are expected to grow to nearly 15% of total international sales in 2026, up from less than 5% in 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the acceleration catalysts and growth expectations for 2026?
A:The company is focusing on increasing its presence in the pharmacy channel, implementing FreeStyle Libre 3, and launching the tubeless version of Mobi. These initiatives, along with Control-IQ, are expected to significantly change the competitive dynamics and drive growth throughout 2026. The company also anticipates seasonality and expects to show more leverage across the year from investments made.
Q:What is the pricing uplift expected from supplies going through the pharmacy?
A:The company has not provided detailed guidance but indicated that the pricing benefit seen in Q3 and Q4 of this year serves as a solid baseline for 2026. More detailed guidance will be provided at the year-end earnings call.
Q:What are the assumptions for seasonality in Q4 compared to last year?
A:The company expects Q4 shipments to be similar to last year, with about 30% of full-year shipments landing in Q4. Renewals are expected to be slightly more than half of the shipments, with a step-up from Q3 to Q4 driven by new renewal opportunities.
Q:What percentage of renewals and new patients were seen in the last quarter?
A:Renewals accounted for slightly more than half of the shipments, while new start populations saw about two-thirds from MDI conversions. There was continued pressure on new starts, which was factored into the updated guidance.
Q:What are the expectations for MDI conversions and market growth in 2026?
A:The company expects MDI conversions to grow, driven by increased presence in the pharmacy channel, reduced out-of-pocket costs for patients, and new product innovations like FreeStyle Libre 3 and Mobi Android. These factors are expected to return the company to double-digit growth.
Q:What is the current status of pharmacy coverage for Mobi?
A:The company has contracts with all major PBMs, covering 40% of payer lines. Efforts are ongoing to improve access within these plans and expand coverage. The company is preparing to scale pharmacy operations efficiently for a larger push in 2026.
Q:What are the gross margin expectations for Q4 and 2026?
A:Q4 gross margins are expected to be in the mid-to-high 50s, driven by U.S. pump sales and the introduction of t:slim supplies in the pharmacy channel. By the end of 2026, gross margins are expected to reach 60%.
Q:What are the expectations for pricing in the pharmacy channel over the long term?
A:While there is a risk of pricing pressure in the long term, the company sees significant near-term opportunities for price appreciation compared to DME. The company aims to build a stable business in the pharmacy channel and mitigate long-term pricing risks.
Q:What is the strategy for launching Sigi and Mobi Tubeless?
A:Mobi Tubeless will be the first extended wear pump in the market and will launch with a 7-day wear capability. Sigi is considered the next-generation Mobi product and will be part of the growing Mobi brand. The company plans to prioritize Mobi Tubeless to bring it to market faster.
Q:What CGM systems will the fully closed-loop system integrate with?
A:The fully closed-loop system will work with all CGMs currently integrated with the company's products. The system is being developed in collaboration with UVA and is expected to enter pivotal trials next year.
Q:What drove the strength in O-U.S. supplies and what is the impact of the $10 million headwind?
A:The strength in O-U.S. supplies was driven by low double-digit growth in placements and favorable foreign currency dynamics. The $10 million headwind is attributed to distributor destocking and is expected to have a stronger impact in Q4.
Q:What are the expectations for Type 2 diabetes market growth?
A:The company is leveraging lessons from pilot programs and has started a full commercial launch for Type 2 diabetes. Pharmacy channel access and tubeless products are expected to improve uptake. The company aims to double its addressable market with these initiatives.
Q:What is the timeline for Mobi Tubeless launch?
A:Mobi Tubeless is expected to launch in 2026, with the company prioritizing its development to bring it to market as quickly as possible. The product will feature a 7-day wear capability and is expected to drive significant business opportunities.
Q:What is the structure of pharmacy contracts for Mobi?
A:Current pharmacy contracts are structured like traditional DME reimbursement models, with upfront payment for pumps and ongoing reimbursement for supplies. The company is exploring other reimbursement models to optimize access.
Q:What are the expectations for double-digit growth?
A:The company aims for sustained double-digit growth with a dual focus on profitability, driven by new product launches, pharmacy channel expansion, and commercial transformation.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the pricing uplift expected from supplies going through the pharmacy, the exact timeline for Mobi Tubeless launch, and the percentage of new patient starts for Type 2 diabetes. Additionally, they did not clarify the exact structure of future pharmacy contracts or provide detailed guidance on MDI conversion growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASP increase
ASP uplift
ASPs combination
ASPs market
Abbott
Europe
Executive VP
PBMs
SGA
Tandem
Type diabetes
app
currency
customer base
expectation sale
feedback
focus
highlight
implementation
initiative
inventory
leader
margin improvement
margin leverage
margin percentage
milestone
momentum
multichannel
opportunity market
people Type
percentage point
pharmacy access
point sale
potential
record sale
reduction
resource
restructuring
rollout
sale benefit
shipment expectation
stock
technology people
testament
transformation
world
TNDM Transcript
Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Positive5-10
The earnings call highlights strong financial performance, with a 10% revenue increase and a significant improvement in net income from a loss to a profit. Gross margins improved by 2%, indicating cost efficiency, and cash flow from operations increased by 25%, suggesting strong operational performance. Despite the lack of discussion on operational updates and strategic initiatives, the positive financial metrics and successful product launches contribute to a positive sentiment.
Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call highlights strong product development, strategic market shifts, and optimistic future guidance. Despite some headwinds, the company anticipates revenue growth driven by new technology and market expansion, with gross margins expected to improve significantly. The transition to a pharmacy model and international direct sales are strategic moves that promise long-term benefits. Analysts' questions reflect confidence in the company's strategy, despite some uncertainties. Given the market cap, the positive sentiment from product launches and strategic transitions is likely to result in a positive stock price movement over the next two weeks.
TNDM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
